The Data and Safety Monitoring Program (DSMP) has been reviewed and approved by the UAB IRB and the NCI. It provides procedures for rigorous monitoring of all Cancer Center therapeutic clinical trials consistent with national and institutional guidelines. It utilizes three Cancer Center entities in addition to the UAB IRB - (1) the Clinical Trial Monitoring Committee (CTMC), (2) the Quality Assurance Committee (QAC), and (3) the Clinical Trial Network and Monitoring (CTNM) Office. The CTMC meets weekly to rigorously review patient data and safety by specific disease sites so that each clinical trial has oversight at least monthly with documentation of review and reports to the QAC (e.g. breast and melanoma - first Friday;Gl and GU - second Friday, etc.). The QAC meets monthly and reviews CTMC reports and reports of QAC internal audits on investigator-initiated trials not otherwise audited. These internal QAC audits average 24/year. The CTNM Office provides investigators with the capacity for IND held and/or multi-institutional trials. It provides the """"""""sponsor"""""""" responsibilities including source document verification, monitoring, and FD/VIRB reporting as well as multi-site coordination and oversight. The DSMP of the Cancer Center provides assurance of the quality and safety of clinical trials for patient participants and clinical investigators according to federal and institutional guidelines.

Public Health Relevance

The Data Safety and Monitoring Program is a critical component to coordinating high quality clinical and translational research. Thus, this program is extremely relevant to a primary mission of the Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA013148-42
Application #
8738180
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
42
Fiscal Year
2014
Total Cost
$188,800
Indirect Cost
$63,251
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Subramaniam, Akila; Blanchard, Christina T; Erickson, Britt K et al. (2018) Feasibility of Complete Salpingectomy Compared With Standard Postpartum Tubal Ligation at Cesarean Delivery: A Randomized Controlled Trial. Obstet Gynecol 132:20-27
Kasten, Benjamin B; Oliver, Patsy G; Kim, Harrison et al. (2018) 212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. Int J Mol Sci 19:
Stoll, Matthew L; Weiss, Pamela F; Weiss, Jennifer E et al. (2018) Age and fecal microbial strain-specific differences in patients with spondyloarthritis. Arthritis Res Ther 20:14
Garner, Evan F; Williams, Adele P; Stafman, Laura L et al. (2018) FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts. Sci Rep 8:6913
Locke, Landon W; Kothandaraman, Shankaran; Tweedle, Michael et al. (2018) Use of a leukocyte-targeted peptide probe as a potential tracer for imaging the tuberculosis granuloma. Tuberculosis (Edinb) 108:201-210
Fancy, Romone M; Kim, Harrison; Napier, Tiara et al. (2018) Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells. J Cell Biochem 119:6216-6230
Barrington, David A; Champion, Macie L; Boitano, Teresa K L et al. (2018) Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic. Gynecol Oncol 149:337-340
Banerjee, N Sanjib; Wang, Hsu-Kun; Beadle, James R et al. (2018) Evaluation of ODE-Bn-PMEG, an acyclic nucleoside phosphonate prodrug, as an antiviral against productive HPV infection in 3D organotypic epithelial cultures. Antiviral Res 150:164-173
Keene, Kimberly S; King, Tari; Hwang, E Shelley et al. (2018) Molecular determinants of post-mastectomy breast cancer recurrence. NPJ Breast Cancer 4:34
Kleinpeter, Alex B; Jureka, Alexander S; Falahat, Sally M et al. (2018) Structural analyses reveal the mechanism of inhibition of influenza virus NS1 by two antiviral compounds. J Biol Chem 293:14659-14668

Showing the most recent 10 out of 747 publications